Hongmei Jing

机构：Peking University, Peking University Third Hospital, Shaanxi Normal University · ORCID：0000-0003-4958-2489

发表论文 349 篇 · 总被引 2973 次 · h-index 27

代表论文

• Machine‐Learning‐Designed BCZT–SBT Heterointerface Unlocks Fatigue‐Resistant Energy Storage (2025 · Advanced Materials · 被引 13)
• Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults (2025 · Blood Advances · 被引 5)
• Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2025 · Blood · 被引 3)
• A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma (2025 · Cell Reports Medicine · 被引 3)
• Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma (2025 · Experimental Hematology and Oncology · 被引 3)
• Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma (2026 · JAMA · 被引 2)